Morales et al. AUR200, novel BAFF/APRIL inhibitor. Looking promising in pre-clinical and animal models. We will wait and see! @RheumNow #ACR22 Abstr#1629 https://t.co/htmX2GHV3X https://t.co/jvhFdx2c52

• AUR200: An Improved BAFF/APRIL Inhibitor with Increased Potency and Safety for …

MOA of how steroids cause #osteoporosis #ACR22 @rheumnow https://t.co/k6MvftH4AV

Lin et al. Genetic risk (HR 2.3 women, 2.63 men) and lifestyle (HR 5.7 for women, 3.7 for men) both individual contributors and synergistic (HR 9.1 women, 8.7 men) in gout development in both men and women. Modifiable! @RheumNow #ACR22 Abstr#1633 https://t.co/51KPgfXn1w https://t.co/gOU7DfOKvt

• Genetic Risk, Adherence to a Healthy Lifestyle, and Incident Gout in US Women a…

PMR is no a disease of vague shoulder and hip pain. It's something much more specific: a chronic inflammatory disease of musculotendinous structures. We're starting to understand the real story. @drceowen lays it out for #ACR22 this morning @EBRheum @SattuiSEMD @RheumNow https://t.co/thqtCwSULM

Bimekizumab (BKZ) in AxSpA to Wk52 ◦ sustained efficacy ◦ suppression of inflammation ◦ improvements in function and quality of life ◦ no new safety signals were observed ◦ consistent with the safety profileWk24 data Baraliakos #L14 https://t.co/gk23g4vqQl #ACR22 @RheumNow

• Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent S…

Fernandes et al. CPPD assoc increased nephrolithiasis. 8.06% vs 4.88%; p<0.0001. @RheumNow #ACR22 Abstr#1819 https://t.co/o8Afmcc429 https://t.co/3EoOXpqpGN

• Calcium Pyrophosphate Deposition Disease Is Associated with an Increased Preval…

Chen et al. Appendicitis associated increased risk incident SLE in population-based case-control study from Taiwan. HR 2.04 @RheumNow #ACR22 Abstr#1750 https://t.co/L9dTpMdHNP https://t.co/mEHeL6JnuE

• Association Between Appendicitis and the Risk of Systemic Lupus Erythematosus: …

Parperis et al. Cypriot population based study. ACS in CPPD assoc longer LOS, and increased mortality 6.9% vs 5.6% (p<0.001). @RheumNow #ACR22 Abstr#1817 https://t.co/uWv67aZa9L https://t.co/3oRFXREcYx

• Acute Coronary Syndrome in Calcium Pyrophosphate Deposition Disease Patients: A…

Helget et al. Subanalysis of STOP Gout. Allopurinol and febuxostat equal efficacy in CKD 3. More AKI with allopurinol 8.3% vs 2.4%. @RheumNow #ACR22 Abstr#1829 https://t.co/Z4JqYp4mTT https://t.co/xd8VGJVkNo

• Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chr…

Low dose #glucocorticoids in rheumatic diseases can lower bone mass and increase # even 2.5 mg #prednisone. The change in #BMD was more predictive of fracture not absolute BMD. L01 #ACR22 #ACRBest @RheumNow https://t.co/MbTk0L4DoK

Mortality in patients with SpA Abstract #0569 #ACR22 @RheumNow ✏️systematic review/meta-analysis of 19 studies ✋No increased mortality in patients with PsA compared to gen. pop. 🦠Infection, 🫀CV, and 🫁 pulm. specific mortality sig. higher in PsA patients

How do we know what PMR is all about? Imaging has helped enormously, and every step of the way, imaging has got better and better. Specific findings which reveal the culpable pathology. @drceowen #ACR22 @RheumNow https://t.co/4OOOk0F3jW

NSAIDs and CV risk in Inflammatory Arthritis Dr. Richard Conway discusses abstract 1207, being presented #ACR22 meeting. https://t.co/CjU2YbA3tk https://t.co/bHE4xw2IRF

• https://bit.ly/3WZ6P6D

#ACR2022 L07: Telitacicept - anti-BlyS and APRIL in SLE 335 pts P3 52 wk study TEL 160 mg SQ q7d vs PBO 83% SRI4 response in TEL vs 38% PBO (p<0.001) As early as w4, sustained to w52 Most common AEs: URIs, decr IgG/IgM, injxn site rxn, UTI @RheumNow #ACRBest https://t.co/UpEwEaonDO

Khanna et al Transdermal NaHCO₃ in gout flare. N=98. Response rate D7 95% vs 79% (p=0.01). Lower rescue med, 6% vs 20%. @RheumNow #ACR22 Abstr#1787 https://t.co/DWtlvjzBHw https://t.co/DOk993gCwz

• The Impact of Topically Applied pH Modulator on Acute Inflammatory Pain, Serum …